This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval
by Zacks Equity Research
Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.
Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow
by Zacks Equity Research
Bruker's (BRKR) ENRICH-iST kit is ready to use right out of the box. The workflow is simple to understand and fully automatable.
Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
by Zacks Equity Research
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod
by Zacks Equity Research
Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.
UnitedHealth Group (UNH) Hikes Quarterly Dividend by 14%
by Zacks Equity Research
UnitedHealth Group's (UNH) recent dividend hike highlights a solid financial position and efforts to sustain its sound capital deployment history.
Inari Medical (NARI) Launches New Catheters to Address VTE
by Zacks Equity Research
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.
3 Reasons to Retain Intuitive Surgical (ISRG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.
Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves
by Zacks Equity Research
Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.
Masimo's (MASI) New FDA Approval to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
Penumbra (PEN) Launches New Technology for Blood Clot Removal
by Zacks Equity Research
Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Revvity (RVTY) Launches New System for Autoimmune Diagnostics
by Zacks Equity Research
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.
HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer
by Zacks Equity Research
Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.
Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?
by Zacks Equity Research
The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.
Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Illumina's (ILMN) New AI Tool to Predict Genomics Disease
by Zacks Equity Research
Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves
by Zacks Equity Research
Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.
Charles River (CRL) to Build RightSource Lab With New Pact
by Zacks Equity Research
Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.